Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
ai16z Founder: no control over AI Pool, no access to private keys

ai16z Founder: no control over AI Pool, no access to private keys

Bitget2024/12/28 21:33

Shaw, the founder of ai16z, has responded to the AI Pool project, which has been getting a lot of attention in the market lately, in a new interview. Shaw, who has endorsed the project several times on social media before, explained that AI Pool is a project of his partner Skely, and is simply based on ElizaOS technology. The program operates like pump.fun, but the entire process is integrated into the social media platform, making it easier and fairer for users to participate.

Shaw emphasizes the autonomy of the project, saying that it exhibits the characteristics of a true autonomous agent - the project is completely self-governing and even ai16z can't intervene: there is no access to private keys, no way to extract funds, and no way to manipulate the project's operation.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

"No-drill dental filling" company vVardis (VVVV.US) launches a $214 million US IPO, scheduled to be priced this week.

Dental treatment company vVardis has announced the terms for its $214 million US IPO.

智通财经•2026/11/09 06:41
"No-drill dental filling" company vVardis (VVVV.US) launches a $214 million US IPO, scheduled to be priced this week.

Wegovy improves multiple liver indicators in non-obese liver disease patients, and Novo Nordisk (NVO.US) is expected to expand its market beyond weight loss

Novo Nordisk reports that some patients treated with Wegovy have shown improvements in liver conditions.

智通财经•2026/11/09 06:41
Wegovy improves multiple liver indicators in non-obese liver disease patients, and Novo Nordisk (NVO.US) is expected to expand its market beyond weight loss